Interactions of macrophages with probiotic bacteria lead to increased antiviral response against vesicular stomatitis virus
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Interactions of macrophages with probiotic bacteria lead to increased antiviral response against vesicular stomatitis virus. / Ivec, Martin; Botic, Tanja; Koren, Srecko; Jakobsen, Mogens; Weingartl, Hana; Cencic, Avrelija.
In: Antiviral Research, Vol. 75, No. 3, 2007, p. 266-274.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Interactions of macrophages with probiotic bacteria lead to increased antiviral response against vesicular stomatitis virus
AU - Ivec, Martin
AU - Botic, Tanja
AU - Koren, Srecko
AU - Jakobsen, Mogens
AU - Weingartl, Hana
AU - Cencic, Avrelija
PY - 2007
Y1 - 2007
N2 - Macrophages are an important cellular component of the innate immune system and are normally rapidly recruited and/or activated at the site of virus infection. They can participate in the antiviral response by killing infected cells, by producing antiviral cytokines such as nitric oxide and by producing chemokines and immunoregulatory cytokines that enable the adaptive immune response to recognize infected cells and perform antiviral effector functions. Probiotics, as a part of the normal gut intestinal flora, are important in supporting a functional yet balanced immune system. Improving our understanding of their role in the activation of macrophages and their stimulation of proinflammatory cytokine production in early viral infection was the main goal of this study. Our in vitro model study showed that probiotic bacteria, either from the species Lactobacillus or Bifidobacteria have the ability to decrease viral infection by establishing the antiviral state in macrophages, by production of NO and inflammatory cytokines such as interleukin 6 and interferon-gamma. These effects correlated with the mitochondrial activity of infected macrophages, therefore, the measurements of mitochondrial dehydrogenases activity could be implied as the first indicator of potential inhibitory effects of the probiotics on virus replication. The interactions between probiotic bacteria, macrophages and vesicular stomatitis virus (VSV), markedly depended on the bacterial strain studied.
AB - Macrophages are an important cellular component of the innate immune system and are normally rapidly recruited and/or activated at the site of virus infection. They can participate in the antiviral response by killing infected cells, by producing antiviral cytokines such as nitric oxide and by producing chemokines and immunoregulatory cytokines that enable the adaptive immune response to recognize infected cells and perform antiviral effector functions. Probiotics, as a part of the normal gut intestinal flora, are important in supporting a functional yet balanced immune system. Improving our understanding of their role in the activation of macrophages and their stimulation of proinflammatory cytokine production in early viral infection was the main goal of this study. Our in vitro model study showed that probiotic bacteria, either from the species Lactobacillus or Bifidobacteria have the ability to decrease viral infection by establishing the antiviral state in macrophages, by production of NO and inflammatory cytokines such as interleukin 6 and interferon-gamma. These effects correlated with the mitochondrial activity of infected macrophages, therefore, the measurements of mitochondrial dehydrogenases activity could be implied as the first indicator of potential inhibitory effects of the probiotics on virus replication. The interactions between probiotic bacteria, macrophages and vesicular stomatitis virus (VSV), markedly depended on the bacterial strain studied.
KW - Former LIFE faculty
KW - Macrophages; Lactobacillus; Bifidobacteria; Antiviral activity; NO; Inflammatory cytokines
U2 - 10.1016/j.antiviral.2007.03.013
DO - 10.1016/j.antiviral.2007.03.013
M3 - Journal article
C2 - 17512614
VL - 75
SP - 266
EP - 274
JO - Antiviral Research
JF - Antiviral Research
SN - 0166-3542
IS - 3
ER -
ID: 8108437